Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $3.58, but opened at $3.77. Evotec shares last traded at $3.85, with a volume of 32,036 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday.
View Our Latest Stock Report on EVO
Evotec Price Performance
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The company's 50-day moving average price is $3.65 and its 200-day moving average price is $4.08.
Institutional Trading of Evotec
Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of Evotec during the 4th quarter worth about $27,000. Bank of America Corp DE increased its stake in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. CSS LLC IL acquired a new stake in Evotec during the fourth quarter worth approximately $50,000. DCF Advisers LLC lifted its position in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after buying an additional 12,816 shares during the last quarter. Finally, Lighthouse Investment Partners LLC acquired a new position in shares of Evotec in the 4th quarter valued at $166,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
